Xeris Biopharma Holdings, Inc.
NASDAQ: XERS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Shannon
- Employees
- 394
- Headquarters
- Chicago, United States
- IPO year
- 2018
- Market cap
- $1.3B
- Website
- https://www.xerispharma.com
Loading XERS…
Loading profile data…Frequently asked questions about XERS
What does Xeris Biopharma Holdings, Inc. (XERS) do?
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia....
Where does XERS trade?
Xeris Biopharma Holdings, Inc. (XERS) trades on the NASDAQ Global Select.
What sector is XERS in?
Xeris Biopharma Holdings, Inc. (XERS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Xeris Biopharma Holdings, Inc.?
John Shannon is the chief executive officer of Xeris Biopharma Holdings, Inc. (XERS).
Where is Xeris Biopharma Holdings, Inc. headquartered?
Xeris Biopharma Holdings, Inc. is headquartered in United States.
Does XERS pay a dividend?
Xeris Biopharma Holdings, Inc. (XERS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did XERS go public?
Xeris Biopharma Holdings, Inc. (XERS) completed its initial public offering in 2018.